"Unreliable" Stocks Rise While Strong Stocks Fall? Do You Have The Same Stocks?
A user on WSB shared that they bought $Reddit(RDDT)$ shares during its IPO and did nothing, yet their investment is now up 150%.
Reddit is known as a platform for meme stocks, with WSB (WallStreetBets) gaining fame during the GME short squeeze battle in 2021. Despite Reddit’s association with meme stocks and its seemingly unreliable reputation, it managed to achieve profitability in this earnings report.
“Unreliable” stocks bring the most profit?
On Tuesday, Reddit announced its first quarterly profit and projected Q4 revenue above expectations, boosted by AI content licensing deals and strong digital ad spending, causing its shares to rise 41% yesterday.
Another example mentioned yesterday is $Carvana Co.(CVNA)$, the used-car platform that has now exceeded earnings expectations for four consecutive quarters, with stock surging after each report.
Carvana beats and jumps over 10% in the past four earnings
In the highly competitive EV market, most carmakers’ stock performance has been lackluster. However, Carvana once again exceeded earnings expectations and raised its full-year profit forecast, spiking 20% in after-hours trading.
Do stocks have two faces?
Some companies appear profitable and undervalued but struggle with persistently declining stock prices, making it hard to profit from them. A prime example of this is Chinese stocks.
Do you have the same experience that seemingly unreliable companies keep rising, while seemingly strong ones see their stocks decline?
Share your experience or other stocks perform like this!
Leave your comments and also post to win tiger coins!!!!
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
I try to secure my investments by doing FA, followed by Technical Analysis to determine the entry and selling price...
These are the stocks that challenged my beliefs...
Favourite $CRDF in open positions
🔺🅱️🆄🅻🅻🅸🆂🅷📈🔬🧬 CRDF: Brewing a Biotech Breakout 🧬🔬📈
Kia ora Tiger traders!
Cardiff Oncology (CRDF) is showing some intriguing moves, but will it deliver the goods or leave us hanging? With its current setup, this could be the trade that turns a few dollars into a jackpot! 🚀📊 Let’s dive into the latest data, chart insights, and market chatter to find out!
📊 Tech Check: The CRDF Chart Rundown 📊
• Current Price: $2.83 (Market Closed, 25 Oct) 📉
• Post-Market: $2.94 (+3.89%) 📈
• 52-Week High: $6.42
• 52-Week Low: $0.94
• Volume: 573.8K
The chart is teasing a classic cup and handle formation, a beloved signal among technical traders. 🏆☕ With eyes set on $3.24 as a breakout target, a successful breach could send CRDF soaring! With the right momentum, this stock could triple its value, pushing towards $8.50 and beyond, mirroring past patterns of aggressive growth in the biotech sector. 📈🚀 Is this the breakout you’ve been waiting for?
💼 Earnings & Financials: Improving, but Still in the Red 💼
• Q2 EPS Loss: -$0.26 (vs. expected -$0.25) 🔴
• Revenue: $0.16M (35.83% above estimates) 📈
• 2024 H1 EPS: -$0.49 (better than -$0.93 in 2023 FY)
Despite the ongoing losses, CRDF has outperformed revenue expectations 4 times in a row. It’s a slow but steady grind up, and those with a long-term vision might see potential where others see volatility. 📉➡️📈
🟢 Positives: Consistent revenue growth, R&D advances, sector tailwinds.
🔴 Negatives: EPS still in negative territory, high short interest (~42.84%).
🧠📊 Analyst Ratings: Majority Bullish, But Caution Remains 🧠📊
• 🟢 Strong Buy: 20%
• 🟢 Buy: 80%
• 🟡 Hold: 0%
• 🔴 Sell: 0%
The sentiment is overwhelmingly positive—80% of analysts recommend buying, hinting at a promising future. Some analysts are hinting at the potential for this stock to triple if it can break free of its resistance zones. However, the Zacks Rank #3 (Hold) suggests caution. The high short interest could lead to volatility, but also a potential short-squeeze scenario. 🏹💣
💸 Capital Flow & Trading Sentiment 💸
CRDF’s turnover rate of 1.33% reflects moderate but stable trading activity. Post-market action shows a bump to $2.94 (+3.89%), signalling renewed interest. Traders are watching key levels:
📍 Resistance:
• $3.24 (Major Target) 🚧 (The breakout could see CRDF surge towards $8.50)
• $3.01 (Immediate Resistance)
🔽 Support:
• $2.66 (MA30 Strong Support)
• $2.73 (Recent Low)
A decisive push past $3.24 could ignite a bullish trend, while a drop below $2.66 may indicate the bears are still in control. 🔄🔮
🏆 Competitive Edge: Where Does CRDF Stand? 🏆
1. Moderna (MRNA)
• 🟢 Buy: 70%
• 🟡 Hold: 20%
• 🔴 Sell: 10%
• Trend: Riding FDA approvals; solid revenue growth 🌟
2. BioNTech (BNTX)
• 🟢 Buy: 60%
• 🟡 Hold: 30%
• 🔴 Sell: 10%
• Trend: Strong partnerships; bullish sentiment 🤝📈
3. Gilead Sciences (GILD)
• 🟢 Buy: 50%
• 🟡 Hold: 40%
• 🔴 Sell: 10%
• Trend: Mixed trial results, robust cash flow 📉💸
CRDF might be a small fish in a big pond, but don’t underestimate its resilience. Will it be the biotech sleeper hit? 🏅🧬💡
🌟 BC’s Final Word: High Stakes or High Potential? 🌟
CRDF is like a Kiwi surfing the biotech waves—risky, thrilling, and unpredictable! 🌊🏄 With the right setup, this stock has the potential to triple in value, making it one to watch. If you’re keen on a potential breakout, now’s the time to keep a close watch on the $3.24 mark. A smooth sail or a wipeout? Only time will tell! 🏄🕶️
Hey Tiger Traders, are you betting on a breakout or waiting for clearer signs? 🤔📈📉
@TigerGPTcould you analyse the historical trends of biotech stocks forming a cup and handle, particularly in high-short-interest environments? 🧠📊
Happy trading ahead. Cheers, BC 🍀
as for me, am quite risk adverse... so I tend to go for stable companies...
@HelenJanet @rL @SPACE ROCKET @TigerGPT @LMSunshine @koolgal @Shyon @Aqa @GoodLife99 @Universe宇宙
Do you have the same experience that seemingly unreliable companies keep rising, while seemingly strong ones see their stocks decline?
Share your experience or other stocks perform like this!
Leave your comments and also post to win tiger coins!!!!
我个人在投资过程中也遇到过类似的情况。例如，我之前观察到一些科技股，明明业绩和增长潜力都非常强劲，但由于市场对于科技行业的短期情绪波动，这些公司的股价却一直处于下跌趋势。同时，我也看过一些看似不太可靠的小公司，尽管它们的盈利和前景并不乐观，但股价却因为投机行为或短期热点持续上涨。这种反差让我意识到，股价短期的波动往往与基本面无关，更多是市场情绪的反映。
因此，作为投资者，我认为在做决策时不仅要关注公司的基本面，还需要考虑市场整体的趋势和情绪因素。长期来看，基本面终将起作用，但在短期内，市场的波动和情绪可能带来一些意想不到的结果，这也是股票市场充满不确定性和挑战的原因之一。
Favourite $CRDF in open positions
🔺🅱️🆄🅻🅻🅸🆂🅷📈🔬🧬 CRDF: Brewing a Biotech Breakout 🧬🔬📈
Kia ora Tiger traders!
Cardiff Oncology (CRDF) is showing some intriguing moves, but will it deliver the goods or leave us hanging? With its current setup, this could be the trade that turns a few dollars into a jackpot! 🚀📊 Let’s dive into the latest data, chart insights, and market chatter to find out!
📊 Tech Check: The CRDF Chart Rundown 📊
• Current Price: $2.83 (Market Closed, 25 Oct) 📉
• Post-Market: $2.94 (+3.89%) 📈
• 52-Week High: $6.42
• 52-Week Low: $0.94
• Volume: 573.8K
The chart is teasing a classic cup and handle formation, a beloved signal among technical traders. 🏆☕ With eyes set on $3.24 as a breakout target, a successful breach could send CRDF soaring! With the right momentum, this stock could triple its value, pushing towards $8.50 and beyond, mirroring past patterns of aggressive growth in the biotech sector. 📈🚀 Is this the breakout you’ve been waiting for?
💼 Earnings & Financials: Improving, but Still in the Red 💼
• Q2 EPS Loss: -$0.26 (vs. expected -$0.25) 🔴
• Revenue: $0.16M (35.83% above estimates) 📈
• 2024 H1 EPS: -$0.49 (better than -$0.93 in 2023 FY)
Despite the ongoing losses, CRDF has outperformed revenue expectations 4 times in a row. It’s a slow but steady grind up, and those with a long-term vision might see potential where others see volatility. 📉➡️📈
🟢 Positives: Consistent revenue growth, R&D advances, sector tailwinds.
🔴 Negatives: EPS still in negative territory, high short interest (~42.84%).
🧠📊 Analyst Ratings: Majority Bullish, But Caution Remains 🧠📊
• 🟢 Strong Buy: 20%
• 🟢 Buy: 80%
• 🟡 Hold: 0%
• 🔴 Sell: 0%
The sentiment is overwhelmingly positive—80% of analysts recommend buying, hinting at a promising future. Some analysts are hinting at the potential for this stock to triple if it can break free of its resistance zones. However, the Zacks Rank #3 (Hold) suggests caution. The high short interest could lead to volatility, but also a potential short-squeeze scenario. 🏹💣
💸 Capital Flow & Trading Sentiment 💸
CRDF’s turnover rate of 1.33% reflects moderate but stable trading activity. Post-market action shows a bump to $2.94 (+3.89%), signalling renewed interest. Traders are watching key levels:
📍 Resistance:
• $3.24 (Major Target) 🚧 (The breakout could see CRDF surge towards $8.50)
• $3.01 (Immediate Resistance)
🔽 Support:
• $2.66 (MA30 Strong Support)
• $2.73 (Recent Low)
A decisive push past $3.24 could ignite a bullish trend, while a drop below $2.66 may indicate the bears are still in control. 🔄🔮
🏆 Competitive Edge: Where Does CRDF Stand? 🏆
1. Moderna (MRNA)
• 🟢 Buy: 70%
• 🟡 Hold: 20%
• 🔴 Sell: 10%
• Trend: Riding FDA approvals; solid revenue growth 🌟
2. BioNTech (BNTX)
• 🟢 Buy: 60%
• 🟡 Hold: 30%
• 🔴 Sell: 10%
• Trend: Strong partnerships; bullish sentiment 🤝📈
3. Gilead Sciences (GILD)
• 🟢 Buy: 50%
• 🟡 Hold: 40%
• 🔴 Sell: 10%
• Trend: Mixed trial results, robust cash flow 📉💸
CRDF might be a small fish in a big pond, but don’t underestimate its resilience. Will it be the biotech sleeper hit? 🏅🧬💡
🌟 BC’s Final Word: High Stakes or High Potential? 🌟
CRDF is like a Kiwi surfing the biotech waves—risky, thrilling, and unpredictable! 🌊🏄 With the right setup, this stock has the potential to triple in value, making it one to watch. If you’re keen on a potential breakout, now’s the time to keep a close watch on the $3.24 mark. A smooth sail or a wipeout? Only time will tell! 🏄🕶️
Hey Tiger Traders, are you betting on a breakout or waiting for clearer signs? 🤔📈📉
@TigerGPTcould you analyse the historical trends of biotech stocks forming a cup and handle, particularly in high-short-interest environments? 🧠📊
Happy trading ahead. Cheers, BC 🍀